Correlation of expression of multidrug resistance protein and messenger RNA with 99mTc-methoxyisobutyl isonitrile (MIBI) imaging in patients with hepatocellular carcinoma

doi:10.3748/wjg.v10.i9.1281

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 9

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2421)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

281

HTML

1776

Figures (1-1)

190

Tables (1-3)

174

Sum=2421

May 1, 2004 (publication date) through Nov 22, 2024

Times Cited of This Article

Times Cited (15)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Liver Cancer

World J Gastroenterol. May 1, 2004; 10(9): 1281-1285
Published online May 1, 2004. doi: 10.3748/wjg.v10.i9.1281

Correlation of expression of multidrug resistance protein and messenger RNA with ^99mTc-methoxyisobutyl isonitrile (MIBI) imaging in patients with hepatocellular carcinoma

Hai Wang, Xiao-Ping Chen, Fa-Zu Qiu

Hai Wang, Xiao-Ping Chen, Fa-Zu Qiu, Hepatic Center of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, HuBei Province, China

Author contributions: All authors contributed equally to the work.

Supported by Clinical Focal Point Subject Foundation of Ministry of Public Health, No.3212001

Correspondence to: Dr. Xiao-Ping Chen, Hepatic Surgery Center of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China. chenxp53@sina.com

Telephone: +86-27-83662599 Fax: +86-27-83662851

Received: March 12, 2003
Revised: July 20, 2003
Accepted: August 16, 2003
Published online: May 1, 2004

Abstract

AIM: To explore whether P-glycoprotein (Pgp) and other pumps, multidrug resistance-associated protein (MRP) and lung resistance protein (LRP), could affect tumor accumulation and efflux of ^99mTc-MIBI in liver cancer.

METHODS: Surgically treated 78 liver cancer patients were included in this study. Before surgery, ^99mTc-MIBI SPECT was performed 15 min and 120 min after injection of 20 mCi ^99mTc-MIBI, respectively. Early uptake, delayed uptake (L/Nd), and washout rate (L/Nwr) of ^99mTc-MIBI were obtained. Expressions of Pgp, MRP and LRP were investigated with Western blotting and immunohistochemistry. Messenger RNA (mRNA) level of Pgp, MRP and LRP was determined by RT-PCR.

RESULTS: No ^99mTc-MIBI uptakes in tumor lesions of 68 of 78 (87.2%) patients with hepatocellular carcinoma were found on ^99mTc-MIBI SPECT. P-gp expression was observed in tumor tissues of the patients with no uptake of ^99mTc-MIBI (P < 0.017). No appreciable correlation was found between liver cancer ^99mTc-MIBI images and expression of MRP or LRP on the level of protein or mRNA.

CONCLUSION: ^99mTc-MIBI SPECT is noninvasive, and useful in predicting the presence of MDR1 gene-encoded Pgp in patients with hepatocellular carcinoma.

Keywords: $[Keywords]